Aprea Therapeutics

• United States

Sources: sec.gov

• ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDS

  Collaborator, Phase 1, Not yet recruiting, 36 people, Jun 1, 2026

• APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)

  Phase 1, Terminated, 4 people, Nov 20, 2020

• APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)

  Phase 1/2, Terminated, 1 person, Jun 5, 2020

• APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies

  Phase 1, Completed, 51 people, Jan 2, 2020

• APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant

  Phase 2, Completed, 33 people, Apr 30, 2019

• APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)

  Phase 3, Completed, 154 people, Nov 19, 2018

• NCT03588078

  Collaborator, Phase 1/2, Completed, 53 people, Jul 17, 2018

• NCT03072043

  Collaborator, Phase 1/2, Completed, 55 people, Mar 7, 2017

Sources: clinicaltrials.gov

• Series C

  $62.3M, Feb 1, 2019

• Series B

  $50M, Oct 1, 2017

• Series B

  $22.6M, Mar 1, 2016

Sources: sec.gov

• 5AM Ventures

  Series C, $6.2M, Feb 1, 2019

• Versant Ventures

  Series C, $6.2M, Feb 1, 2019

• Sectoral Asset Management

  Series C, $5.6M, Feb 1, 2019

• HealthCap

  Series C, $5.1M, Feb 1, 2019

• 5AM Ventures

  Series B, $13.8M, Mar 1, 2016

• Versant Ventures

  Series B, $13.8M, Mar 1, 2016

• Sectoral Asset Management

  Series B, $6.9M, Mar 1, 2016

• HealthCap

  Series B, $11.5M, Mar 1, 2016

Sources: sec.gov

• Patient-reported frailty phenotype (PRFP) vs. International Myeloma Working Group frailty index (IMWG FI) proxy: A comparison between two approaches to measuring frailty

  Consulting or advice, Dec 16, 2023

Sources: pubmed.ncbi.nlm.nih.gov